CD54-NOTCH1 axis controls tumor initiation and cancer stem cell functions in human prostate cancer

Cancer stem cells (CSCs) are considered one of the key contributors to chemoresistance and tumor recurrence. Therefore, the precise identification of reliable CSC markers and clarification of the intracellular signaling involved in CSCs remains a great challenge in fields relating to cancer biology....

Full description

Bibliographic Details
Main Authors:	Li, Chong, Liu, Shengwu, Yan, Ruping, Han, Ning, Wong, Kwok-Kin, Li, Lei
Format:	Online
Language:	English
Published:	Ivyspring International Publisher 2017
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5196886/

id	pubmed-5196886
recordtype	oai_dc
spelling	pubmed-51968862017-01-01 CD54-NOTCH1 axis controls tumor initiation and cancer stem cell functions in human prostate cancer Li, Chong Liu, Shengwu Yan, Ruping Han, Ning Wong, Kwok-Kin Li, Lei Research Paper Cancer stem cells (CSCs) are considered one of the key contributors to chemoresistance and tumor recurrence. Therefore, the precise identification of reliable CSC markers and clarification of the intracellular signaling involved in CSCs remains a great challenge in fields relating to cancer biology. Here, we implemented a novel chemoresistant prostate cancer patient-derived xenograft (PDX) model in NOD/SCID mice and identified CD54 as a candidate gene among the most highly enriched gene expression profiles in prostate tumors exposed to chronic cisplatin administration. Additional in vitro and in vivo assays showed that CD54 played a critical role in the self-renewal and tumorigenesis of prostate CSCs. Moreover, silencing CD54 greatly reduced the tumorigenesis of prostate cancers both in vitro and in vivo and significantly extended the survival time of tumor-bearing mice in a prostate cancer xenograft model. Dissection of the molecular mechanism revealed that the p38-Notch1 axis was the main downstream signaling pathway in CD54-mediated regulation of CSCs in prostate cancers. Together, these results established that CD54 could be a novel reliable prostate CSC marker and provided a new potential therapeutic target in prostate cancer via CD54-Notch1 signaling. Ivyspring International Publisher 2017-01-01 /pmc/articles/PMC5196886/ /pubmed/28042317 http://dx.doi.org/10.7150/thno.16752 Text en © Ivyspring International Publisher. Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. See http://ivyspring.com/terms for terms and conditions.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Li, Chong Liu, Shengwu Yan, Ruping Han, Ning Wong, Kwok-Kin Li, Lei
spellingShingle	Li, Chong Liu, Shengwu Yan, Ruping Han, Ning Wong, Kwok-Kin Li, Lei CD54-NOTCH1 axis controls tumor initiation and cancer stem cell functions in human prostate cancer
author_facet	Li, Chong Liu, Shengwu Yan, Ruping Han, Ning Wong, Kwok-Kin Li, Lei
author_sort	Li, Chong
title	CD54-NOTCH1 axis controls tumor initiation and cancer stem cell functions in human prostate cancer
title_short	CD54-NOTCH1 axis controls tumor initiation and cancer stem cell functions in human prostate cancer
title_full	CD54-NOTCH1 axis controls tumor initiation and cancer stem cell functions in human prostate cancer
title_fullStr	CD54-NOTCH1 axis controls tumor initiation and cancer stem cell functions in human prostate cancer
title_full_unstemmed	CD54-NOTCH1 axis controls tumor initiation and cancer stem cell functions in human prostate cancer
title_sort	cd54-notch1 axis controls tumor initiation and cancer stem cell functions in human prostate cancer
description	Cancer stem cells (CSCs) are considered one of the key contributors to chemoresistance and tumor recurrence. Therefore, the precise identification of reliable CSC markers and clarification of the intracellular signaling involved in CSCs remains a great challenge in fields relating to cancer biology. Here, we implemented a novel chemoresistant prostate cancer patient-derived xenograft (PDX) model in NOD/SCID mice and identified CD54 as a candidate gene among the most highly enriched gene expression profiles in prostate tumors exposed to chronic cisplatin administration. Additional in vitro and in vivo assays showed that CD54 played a critical role in the self-renewal and tumorigenesis of prostate CSCs. Moreover, silencing CD54 greatly reduced the tumorigenesis of prostate cancers both in vitro and in vivo and significantly extended the survival time of tumor-bearing mice in a prostate cancer xenograft model. Dissection of the molecular mechanism revealed that the p38-Notch1 axis was the main downstream signaling pathway in CD54-mediated regulation of CSCs in prostate cancers. Together, these results established that CD54 could be a novel reliable prostate CSC marker and provided a new potential therapeutic target in prostate cancer via CD54-Notch1 signaling.
publisher	Ivyspring International Publisher
publishDate	2017
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5196886/
_version_	1613841239461855232

CD54-NOTCH1 axis controls tumor initiation and cancer stem cell functions in human prostate cancer

Similar Items